Nov 24, 2020 by Jason HawthorneThe Vaccines Are Almost Ready, but the Challenges Are Only BeginningEven when a coronavirus vaccine is ready, distribution could be a challenge -- but recent innovations in medical glass could benefit the public and investors alike.
Nov 24, 2020 by Jason HawthorneOnce the FDA Green Lights a Vaccine, This Is the Next Big Hurdle for InvestorsDemonstrating effectiveness is no small task, but the next challenge may be even greater.
Nov 22, 2020 by Jason HawthorneThis Company's New Approach Could Slash Gilead's Profit From HIV DrugsThe company's HIV franchise faces threats from many different directions.
Nov 21, 2020 by Jason HawthorneIs Gene Editing Already Leaving CRISPR Therapeutics Behind?Innovative companies are trying to ensure that CRISPR Therapeutics' foothold in gene editing doesn't last forever.
Nov 18, 2020 by Jason Hawthorne3 Best Biotech Stocks to Buy in NovemberWhile most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
Nov 18, 2020 by Jason HawthorneWhy Is Everyone Talking About Moderna Stock?The biotech company released positive interim results from its coronavirus vaccine trials.
Nov 17, 2020 by Jason HawthorneCould Inovio Pharmaceuticals Be a Millionaire-Maker Stock?The popularity of coronavirus vaccine makers could blind investors to the risks of this investment.
Nov 16, 2020 by Jason Hawthorne3 No-Brainer Stocks to Buy in HousingThese three companies are benefiting from a booming housing market and trends that may last for decades.
Nov 15, 2020 by Jason HawthorneIs Novartis' Dividend at Risk?Using traditional metrics, it seems in peril, but investors need to take a closer look in order to judge just how safe the payout is.
Nov 15, 2020 by Jason HawthorneInvestors Wish They Could Vote These 2 Healthcare CEOs OutWith immobile stock prices and a hangover of legal issues, these CEOs might be glad Wall Street doesn't operate like a democracy.
Nov 14, 2020 by Jason HawthorneForget Snowflake! Buy This Ultra-High-Growth StockThis device maker is riding the rising tide of continuous glucose monitoring systems.
Nov 14, 2020 by Jason HawthorneForget Apple! Buy These 2 High-Growth Stocks InsteadInstead of investing in the company that would have made you a millionaire years ago, seek out the ones that have the potential from here.
Nov 14, 2020 by Jason HawthorneIs Novavax a Ticking Time Bomb for Investors?The biotech is trying to rewrite its rocky history with a little help from $2 billion in funding for a coronavirus vaccine.
Nov 14, 2020 by Jason HawthorneIs BioNTech Stock a Buy?After big coronavirus vaccine news, investors want to know if Pfizer's partner is still a buy.
Nov 14, 2020 by Jason Hawthorne3 Best Biotech Stocks to Buy Right NowBiotech is on every investor's mind as we move closer and closer to a successful vaccine for the coronavirus. Here are three contenders for your portfolio.
Nov 13, 2020 by Jason Hawthorne3 Dividend Stocks That Pay You Better Than Coca-Cola DoesThese companies are well-positioned to maintain leadership positions in their industries for years to come, and to keep rewarding shareholders with steadily rising payouts.
Nov 11, 2020 by Jason HawthorneForget Livongo: This Is a Better Telehealth StockNow that Teladoc's acquisition of Livongo is complete, the best telehealth stock to buy might surprise some investors.
Nov 11, 2020 by Jason HawthorneCould Pfizer Be a Millionaire-Maker Stock?Big news from the drugmaker on a coronavirus vaccine may be just the first in a string of successes.
Nov 10, 2020 by Jason HawthorneBetter Buy: Moderna vs. BioNTechThere are plenty of similarities between these two makers of coronavirus vaccine candidates, but the few differences make the choice clear.
Nov 10, 2020 by Jason Hawthorne3 Top Small-Cap Stocks to Buy in NovemberTwo well-known brands and a leader in healthcare allow investors to look past giant tech companies for opportunities in small-caps this month.
